DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

which the inhibition of PDE5 prolongs and accentuates. In the pulmonary
bed, inhibition of PDE5 induces vasodilation.
Sildenafil. Sildenafil (REVATIO) is a selective PDE5 inhibitor that is
given at a dose (20 mg three time daily orally) that is lower than used
for erectile dysfunction (100 mg; Chapter 27). It is effective in
lowering pulmonary resistance and improving exercise tolerance in
patients with PAH. Side effects include headache, flushing, dyspepsia,
and visual disturbances.
Tadalafil. Tadalafil (ADCIRCA) has a longer duration of action than
sildenafil so may be suitable for once-daily dosing. It is approved for
World Health Organization group 1 PAH to improve exercise ability.
BIBLIOGRAPHY
Adams NP, Bestall JC, Jones P, et al. Fluticasone at different
doses for chronic asthma in adults and children. Cochrane
Database Syst Rev, 2008, CD003534.
Angus RM, Mecallaum MJA, Hulks G, Thomson NC.
Bronchodilator, cardiovascular and cyclic guanylyl monophosphate
response to high dose infused atrial natriuretic peptide in
asthma. Am Rev Respir Dis, 1993, 147:1122–1125.
Avila PC. Does anti-IgE therapy help in asthma? Efficacy and
controversies. Annu Rev Med, 2007, 58:185–203.
Back M. Functional characteristics of cysteinyl-leukotriene
receptor subtypes. Life Sci, 2002, 71:611–622.
Barnes PJ. Scientific rationale for combination inhalers with a
long-acting 2-agonists and corticosteroids. Eur Respir J,
2002, 19:182–191.
Barnes PJ. Theophylline: New perspectives on an old drug. Am
J Respir Crit Care Med, 2003, 167:813–818.
Barnes PJ. Mediators of chronic obstructive pulmonary disease.
Pharm Rev, 2004, 56:515–548.
Barnes PJ. How corticosteroids control inflammation. Br
J Pharmacol, 2006a, 148:245–254.
Barnes PJ. Treatment with (R)-albuterol has no advantage over
racemic albuterol. Am J Respir Crit Care Med, 2006b,
174:969–972.
Barnes PJ. The problem of cough and development of novel antitussives.
Pulm Pharmacol Ther, 2007, 20:416–422.
Barnes PJ. Cytokine networks in asthma and chronic obstructive
pulmonary disease. J Clin Invest, 2008a, 118: 3546–3556.
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary
disease. Nat Immunol Rev, 2008b, 8: 183–192.
Barnes PJ. Role of HDAC2 in the pathophysiology of COPD.
Ann Rev Physiol, 2009, 71:451–464.
Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory
diseases. Lancet, 2009, 342:1905–1917.
Barnes PJ, Celli BR. Systemic manifestations and comorbidities
of COPD. Eur Respir J, 2009, 33:1165–1185.
Barnes PJ, Chung KF, Page CP. Inflammatory mediators of
asthma: an update. Pharmacol Rev, 1998a, 50:515–596.
Barnes PJ, Karin M. Nuclear factor-B: A pivotal transcription
factor in chronic inflammatory diseases. N Engl J Med, 1997,
336:1066–1071.
Barnes PJ, Liu S-F. Regulation of pulmonary vascular tone.
Pharmacol Rev, 1995, 47:87–131.
Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled
corticosteroids: An update. Am J Respir Crit Care Med, 1998b,
157: S1–S53.
Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable
chronic obstructive pulmonary disease: A meta-analysis.
Thorax, 2006, 61: 854–862.
Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations
of chronic obstructive pulmonary disease: Metaanalysis
of randomised trials. BMJ, 2003, 327: 643.
Basnyat B, Murdoch DR. High-altitude illness. Lancet, 2003,
361: 1967–1974.
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for
asthma management and prevention: GINA executive summary.
Eur Respir J, 2008, 31:143–178.
Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv,
2009, 6: 38–49.
Birring SS, Berry M, Brightling CE, Pavord, ID. Eosinophilic
bronchitis: Clinical features, management and pathogenesis.
Am J Respir Med, 2003, 2:169–173.
Black JL, Armour CL, Johnson PRA, et al. The action of a
potassium channel activator BRL 38227 (lemakalim) on
human airway smooth muscle. Am Rev Respir Dis, 1990,
142:1384–1389.
Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2
polymorphisms on response to longacting beta2-agonist therapy:
A pharmacogenetic analysis of two randomised studies.
Lancet, 2007, 370:2118–2125.
Brenner MR, Berkowitz R, Marshall N, Strunk RC. Need for
theophylline in severe steroid-requiring asthmatics. Clin
Allergy, 1988, 18:143–150.
Broide DH. Immunomodulation of allergic disease. Annu Rev
Med, 2009, 60:279–291.
Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of
pharmacokinetics and systemic effects of inhaled fluticasone
propionate in patients with asthma and healthy volunteers: A
randomised crossover study. Lancet, 2000, 356:556–561.
Burgel PR, Nadel JA. Roles of epidermal growth factor receptor
activation in epithelial cell repair and mucin production in airway
epithelium. Thorax, 2004, 59:992–996.
Calhoun WJ. Anti-leukotrienes for asthma. Curr Opin
Pharmacol, 2001, 1:230–234.
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone
propionate and survival in chronic obstructive pulmonary
disease. N Engl J Med, 2007, 356:775–789.
Casarosa P, Kiechle T, Sieger P, et al. The constitutive activity of
the human muscarinic M3 receptor unmasks differences in the
pharmacology of anticholinergics. J Pharmacol Exp Ther,
2009 December 24 (Epub ahead of print).
Cazzola M. Aclidinium bromide, a novel long-acting muscarinic
M3 antagonist for the treatment of COPD. Curr Opin Investig
Drugs, 2009, 10:482–490.
Cazzola M, Matera MG. Novel long-acting bronchodilators for
COPD and asthma. Br J Pharmacol, 2008, 155:291–299.
Chan HK. Dry powder aerosol delivery systems: Current and
future research directions. J Aerosol Med, 2006, 19:21–27.
Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal
reflux treatment for prolonged non-specific cough in children
and adults. Cochrane Database Syst Rev, 2006, CD004823.
Chiba Y, Shinozaki K, Ueno A, et al. Increased expression of
Ga q
protein in bronchial smooth muscle of mice with allergic
bronchial asthma. J Smooth Muscle Res, 2008, 44:95–100.
Chung IY, Nam-Kung EK, Lee NM, et al. The downregulation of
bcl-2 expression is necessary for theophylline-induced apoptosis
of eosinophil. Cell Immunol, 2000, 203:95–102.
1061
CHAPTER 36
PULMONARY PHARMACOLOGY